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Abstract
Background: Serine proteases are a major component of viper venoms and are thought to disrupt several distinct elements
of the blood coagulation system of envenomed victims. A detailed understanding of the functions of these enzymes is
important both for acquiring a fuller understanding of the pathology of envenoming and because these venom proteins
have shown potential in treating blood coagulation disorders.
Methodology/Principal Findings: In this study a novel, highly abundant serine protease, which we have named
rhinocerase, has been isolated and characterised from the venom of Bitis gabonica rhinoceros using liquid phase isoelectric
focusing and gel filtration. Like many viper venom serine proteases, this enzyme is glycosylated; the estimated molecular
mass of the native enzyme is approximately 36kDa, which reduces to 31kDa after deglycosylation. The partial amino acid
sequence shows similarity to other viper venom serine proteases, but is clearly distinct from the sequence of the only other
sequenced serine protease from Bitis gabonica. Other viper venom serine proteases have been shown to exert distinct
biological effects, and our preliminary functional characterization of rhinocerase suggest it to be multifunctional. It is
capable of degrading a and b chains of fibrinogen, dissolving plasma clots and of hydrolysing a kallikrein substrate.
Conclusions/Significance: A novel multifunctional viper venom serine protease has been isolated and characterised. The
activities of the enzyme are consistent with the known in vivo effects of Bitis gabonica envenoming, including bleeding
disorders, clotting disorders and hypotension. This study will form the basis for future research to understand the
mechanisms of serine protease action, and examine the potential for rhinocerase to be used clinically to reduce the risk of
human haemostatic disorders such as heart attacks and strokes.
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Introduction
Snake venom serine proteases exert their effects through the
ability to disrupt the blood coagulation system of envenomed prey
and victims [1]. They are found mainly in the venoms of snakes
belonging to the viperidae family with a few occurring in members
of the elapidae, colubridae and hydrophidae families [2]. Viper
venom serine proteases (VVSPs) affect various stages of the blood
coagulation system. These include pro-coagulant enzymes such as
thrombin-like enzymes which clot fibrinogen (fibrinogenolytic),
factor V activators, kininogenases and platelet aggregators, and
anti-coagulant enzymes such as fibrinolytic enzymes, plasminogen
activators and protein C activators [3]. Characterised VVSPs
belong to the S1 family within the SA clan of serine proteases; they
contain 230–236 amino acids with molecular masses between
28kDa and 38kDa due to their varying glycosylation contents and
have a chymotrypsin-like structural fold [2]. VVSPs typically
exhibit 60–90% sequence identity with each other and 30–35%
identity with mammalian trypsin and thrombin [4,5]. Despite their
high sequence similarity, there is considerable variation in the
functions of the VVSPs. This functional diversity is conferred
therefore by less than 40% of the total VVSP sequence.
Understanding the relationships between the sequences, struc-
tures and functions of VVSPs is vital for understanding the
specificity of these enzymes and their effects on prey and victims.
The sequences of over 100 VVSPs are known, but only 4 crystal
structures have been determined [6–8]. Detailed functional
information is also limited; our preliminary analysis showed that
no functional information is available for the majority (80%) of
VVSP sequences. From the venom of West African gaboon viper
Bitis gabonica rhinoceros only one serine protease had been sequenced
and no functional analysis was carried out on this protein,
although intriguingly the sequence lacks the classical serine
protease catalytic triad [9]. The existence of other serine proteases
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clotting serine protease [12] has been mentioned in the literature.
To further understanding of this family of venom enzymes there is
a need for detailed functional characterisation of specific VVSPs.
As a step towards this goal here we report the purification, partial
amino acid sequencing and preliminary functional characterisa-
tion of a novel serine protease from the venom of B. g. rhinoceros.
Materials and Methods
Materials used- Lyophilized venom of B. g. rhinoceros was obtained
from a pool of four specimens maintained in the Liverpool School
of Tropical Medicine, Liverpool, UK. Protein molecular weight
markers, polyvinylidene fluoride (PVDF) membranes and aliphatic
ampholytes were from Bio-Rad (Hemel Hempstead, UK). The low
molecular weight column calibration kit, enhanced chemilumi-
nescence (ECL) reagents and ECL glycoprotein detection module
were from GE Healthcare (Amersham, UK). N Glycosidase F
enzyme was from Roche Diagnostics Limited (West Sussex, UK)
and trypsin and thrombin were from Promega (Southampton,
UK). Fluorescent substrates, PROTIA- Proteoprep Immunoaffi-
nity albumin and IgG depletion kit and all other chemicals used in
this research were analytical grade from Sigma Aldrich (Poole,
UK).
SDS-PAGE and Immuno blotting- Reducing SDS-PAGE, staining
and immuno blotting onto polyvinylidine difluoride (PVDF)
membrane were all performed using standard techniques [13].
Serine protease assay- Serine protease activity of venom and
purified proteins was measured using a fluorescent substrate, Na-
benzoyl-L-arginine 7-amido-4-methylcoumarin.HCl (Arg-AMC)
(B7260, Sigma Aldrich) as previously described [14]. Venom or
purified proteins in 0.1M Tris-HCl pH7.4 were mixed with
various concentrations of Arg-AMC along with trypsin and
thrombin as positive controls and incubated at 37uC. The amount
of 7-amido-4-methylcoumarin (AMC) released was measured at
different time points by spectrofluorimeter (FLUOstar OPTIMA,
Offenburg, Germany) at an excitation wavelength of 366 nm and
an emission wavelength of 460 nm. The kinetic parameters were
calculated from Lineweaver-Burk plots. The results are represent-
ed by Km, Vmax, Kcat and Kcat/Km values. All measurements were
performed in triplicate.
Protein purification- A serine protease present in the venom was
purified by liquid phase isoelectric focussing using a micro rotofor
(Bio-Rad, Hemel Hempstead, UK) followed by Superdex 75 gel
filtration using a 16 mm670 cm column. Two milligrams of B. g.
rhinoceros venom were mixed with 3 ml of non-reducing rotofor
buffer [7M urea, 2M thiourea, 10% (v/v) glycerol and 2.5% (v/v)
ampholytes (pI 6–8) in Milli-Q water] and loaded on to the
focussing chamber. Isoelectric focussing was performed under
cooling setting I (temperature between 4uC and 15uC) with the
programmed electric field (150V/2W/20 mA for 15 minutes,
200V/2W/20 mA for 15 minutes, 300V/2W/20 mA for 20
minutes, 350V/2W/20 mA for 20 minutes and 400V/2W/
20 mA for 60 minutes). 0.1M orthophosphoric acid and 0.1M
sodium hydroxide were used as anode and cathode electrode
buffers respectively. Twenty microlitres of separated rotofor
fractions were used to analyse the serine protease activity using
Arg-AMC and 10 ml were used for SDS-PAGE to analyse the
protein separation patterns.
Rotofor fractions with serine protease activity and containing a
highly abundant protein with an approximate molecular mass of
36 kDa were pooled and loaded on to a Superdex 75 column with
a flow rate of 1ml/min in 0.02M Tris-HCl pH 7.4 and collected as
1 ml fractions. Serine protease activity in 100 ml of selected
fractions representing each peak in the chromatogram was
measured using Arg-AMC. Each of these fractions (100 ml) were
analysed by 10% reducing SDS-PAGE. The purified protein was
washed and concentrated by ultrafiltration (30 kDa cut off).
Protein concentration was estimated using a Bradford assay [15].
Specific antibodies against the purified protein were raised in
rabbit using standard protocols [16].
Glycosylation detection and deglycosylation- Twenty micrograms of
purified protein were subjected to (i) 10% reducing SDS-PAGE
followed by transfer to a PVDF membrane and (ii) glycosylation
detection using the ECL glycoprotein detection module according
to the manufacturer’s protocol. Deglycosylation was achieved by
mixing 100 mg of purified protein in 0.02M Tris-HCl pH 7.4 with
5 units of N Glycosidase F and incubating for 10 hours at 37uC.
Sequencing of purified protein- Trypsin was used to digest 100 mgo f
purified protein and the resultant peptides were purified by HPLC
and then subjected to Edman degradation. A silver stained
reducing SDS-PAGE band of purified serine protease was excised
and sequenced by LC-Mass spectrometry (Q-TOF).
Plasma clotting assay- The plasma clotting assay was performed as
previously described [17]. 100 mg of purified protein and different
quantities of thrombin were mixed individually with 500 ml of pre-
incubated human citrated plasma at 37uC before adding 200 mlo f
0.02M CaCl2 to re-calcify the plasma. The mixture was incubated
at 37uC in a water bath and the clotting time recorded.
Fibrinogenolytic assay- This assay was performed as previously
described [18]. 400 ml (5 mg/ml) of plasminogen-free fibrinogen
in 0.05M Tris-HCl; 0.1M NaCl, pH 7.8 were mixed with 100 mg
of purified protein, and the mixture was incubated at 37uCi na
water bath. 25 ml of reaction mix were taken at different time
intervals and mixed with an equal volume of Laemmli reducing
sample treatment buffer immediately to stop the reaction.
Similarly, for the analysis of rhinocerase activity in plasma,
400 ml of human plasma was mixed with 100 mg of rhinocerase
and different concentrations of EDTA, and the mixture was
incubated at 37uC in a water bath. Fifty microlitres of reaction mix
were taken at different time points and mixed with 50 mlo f
Proteoprep immunoaffinity equilibration buffer and passed
through the Proteoprep immunoaffinity albumin and IgG
depletion spin columns according to the manufacturer’s protocols.
The column was washed once with 150 ml of Proteoprep
immunoaffinity equilibration buffer and the eluate was mixed
with previously collected unbound plasma proteins. Fifty micro-
litres of the 250 ml of unbound plasma proteins were mixed with
an equal volume of Laemmli reducing sample treatment buffer.
The bound plasma proteins were eluted with 300 ml of Proteoprep
protein extraction reagent type 4 and this was analysed to ensure
the absence of any target proteins bound to the column. All
samples were analysed by 10% reducing SDS-PAGE.
Fibrinolytic assay- Human citrated plasma (500 ml) was mixed
with 2 units of thrombin at 37uC in a water bath before adding
100 ml of 0.02M CaCl2 and incubated until the formation of a clot.
The clot was transferred to another clean test tube and 100 mgo f
purified protein or buffer were added and incubated at 37uC
overnight.
Fibrinolytic activity was also analysed with a fluorescent plasmin
substrate [Ala-Leu-Lys-AMC (D-Ala-Leu-Lys-7-amido-4-methyl-
coumarin) A8171, from Sigma Aldrich, Poole, UK]. Plasmin
substrate at various concentrations was incubated with 100 mgo f
purified protein or venom in 0.1M Tris-HCl pH 7.4 at 37uC. The
amount of AMC released was measured at different time points at
an excitation wavelength of 366 nm and an emission wavelength
of 460 nm. The kinetic parameters were calculated as described
for Arg-AMC.
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krein-like) and plasminogen activator activities were analysed
using a fluorescent glandular kallikrein substrate [Ala-Leu-Arg-
AMC (D-Ala-Leu-Arg-7-amido-4-methylcoumarin) - V2763] and
a fluorescent uPA (urokinase plasminogen activator) substrate
[Gly-Gly-Arg-AMC (Z-Gly-Gly-Arg-7-amido-4-methylcoumari
hydrochloride) - C9396] respectively (Sigma Aldrich, Poole,
UK). Both substrates, at varying concentrations, were incubated
with 100 mg of purified protein or venom in 0.1M Tris-HCl
pH 7.4 at 37uC separately. The amount of AMC released was
measured and the kinetic parameters were calculated as described
for Arg-AMC.
Platelet aggregation assay- Washed human platelets or platelet rich
plasma (PRP) were prepared as described previously by differential
centrifugation and rested for 30 minutes at 30uC prior to
experimentation [19]. 450 ml of platelets or PRP at a density of
4610
8 cells/ml in modified Tyrodes-HEPES buffer (134 mM
NaCl, 2.9 mM KCl, 0.34 mM Na2HPO4, 12 mM NaHCO3,
1 mM MgCl2, 20 mM HEPES and 5 mM glucose, pH 7.3) were
pre-warmed at 37uC for 90 seconds prior to the addition of 100 mg
of purified protein or 5 mg/ml concentration of collagen related
peptide (CRP) (a collagen receptor glycoprotein VI selective
agonist) or 1 U/ml concentration of thrombin in a siliconised
cuvette in an optical platelet aggregometer (Chrono-Log Corpo-
ration, Havertown, PA, USA) with continuous stirring (1200 g).
Platelet aggregation was measured as previously described [20].
Effect on inhibitors on rhinocerase- Phenyl methylsulphonyl fluoride
(PMSF) at the concentrations of 20, 40, 60, 80 and 100 mM were
incubated with 10 U of thrombin or 100 mg of native or
deglycosylated rhinocerase at 37uC for 30 minutes. The
fluorescent substrate, Arg-AMC was then added to a final
concentration of 50 nM and incubated at 37uC. The amount of
AMC released was measured as described in the previous section.
Results
Serine protease activity of B. g. rhinoceros venom- To determine the
presence of serine proteases in the venom of B. g. rhinoceros, Arg-
AMC was used due to its specificity for trypsin-like serine
proteases. Venom was found to contain serine protease activity
similar to trypsin and thrombin (table 1).
Protein profile of venom- Fractionation of whole B. g. rhinoceros
venom using reducing SDS-PAGE yielded 16 visible protein bands
of varying staining intensities (figure 1A). The molecular masses of
these proteins ranged between 10 kDa and 150 kDa. Eight
proteins were visible between 25 kDa and 40 kDa, the molecular
weight range where serine proteases have been identified.
Purification of serine protease - To purify B. g. rhinoceros venom serine
proteases size exclusion, ion-exchange and affinity column
chromatography were tried either alone or in combination with
limited success. We therefore used liquid phase isoelectric focusing
which separates proteins based on their isoelectric points. Using an
ampholyte range of 6–8 pI (under non-denaturing and non-
reducing conditions), venom proteins were well separated
(figure 1B) and high serine protease activity observed, which
coincided with the presence of two proteins with approximate
molecular masses of 36 kDa and 70 kDa in fractions 3 and 4
(figure 1C). These fractions were pooled and loaded onto a
Superdex 75 gel filtration column. Five clearly resolved protein
peaks (P1, P2, P3, P4 and P5) were identified (figure 2A). Serine
protease activity was measured for single fractions with high
absorbance in fractions P1.1-P1.3 and P2-P5, and was found to be
restricted to peak P2 (figure 2B). Proteins present in these fractions
were separated by reducing SDS-PAGE and visualised by silver
staining. Peak P2 was found to contain a single protein with an
approximate molecular mass of 36 kDa (figure 2C). Peaks P4 and
P5 shown on the figure 2B do not show any proteins in the SDS-
PAGE (figure 2C) indicating the elution of ampholytes, thiourea
and urea present in the rotofor buffer. Consistent with the
toxicological literature, we named this new purified venom serine
protease ‘rhinocerase’. Based on the Bradford assay, 5 mg of
whole B. g. rhinoceros venom yielded 1.12 mg of rhinocerase, thus
this is a major active component which constitutes approximately
25% of the total protein in this venom.
In order to estimate the serine protease activity of rhinocerase,
Arg-AMC was used and the kinetic parameters were calculated for
rhinocerase in comparison with B. g. rhinoceros venom, trypsin and
thrombin (table 1). This analysis showed that the Km value of
rhinocerase was higher than that of trypsin and venom which
indicates that Arg-AMC is a better substrate for trypsin and venom
than rhinocerase. This suggests that the venom might have other
serine proteases which cleave Arg-AMC better than rhinocerase.
However, Arg-AMC was used throughout the purification process
to identify the serine protease activity.
Sequence analysis- N-terminal sequencing of the undigested
protein, together with 4 trypsin digested fragments yielded 89
residues, which comprise approximately 38% of the total sequence
based on the mature venom serine protease sequences (230–235
amino acids) reported so far. The resulting sequence was aligned
with that of Bitis gabonica serine protease 1 (NCBI accession
number: AAR24534) (BGSP) [9], the only published serine
protease sequence from B. gabonica venom and other VVSPs such
as bothrombin (NCBI accession number: P81661) and ancrod
(NCBI accession number: AAA49195). The sequence alignment
(figure 3) shows high similarity between the VVSP sequences,
although BGSP and rhinocerase are clearly distinct.
Data obtained by mass spectrometry of rhinocerase were
searched using the Mascot database [21] and the closest match
Table 1. Specificity of rhinocerase towards Arg-AMC.
Activity (Substrate) Enzyme Km
a (mM) Vmax
a (s
21) Kcat
a (s
21) Kcat/Km x1 0
3a (mM
21s
21)
Serine protease (Arg-AMC) Trypsin 39.1961.19 - 114.3963.6 2919.1366.7
Thrombin 60.665.92 0.4360.03 - -
Venom 6.6660.57 0.0760.003 - -
Rhinocerase 80.0562.02 - 214.5263.9 2680.15620.87
aThe values are mean 6 S.D. (n=3).
100 mg of rhinocerase were incubated with different concentrations of Arg-AMC at 37uC for 7 minutes. The amount of AMC released was measured at an excitation
wavelength of 366 nm and an emission wavelength of 460 nm at time intervals up to 7 minutes. 100 mgo fB. g. rhinoceros venom, 100 mg of trypsin and 10 units of
thrombin were also used at the same experimental conditions for comparison. Kinetic parameters were determined from Lineweaver-Burk plots.
doi:10.1371/journal.pone.0009687.t001
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elegans. The sequence of a short trypsin-digested peptide was found
to be ‘TLCAGVLEGGKD’ and these residues (underlined in
figure 3) were also identified using Edman degradation. This
suggests that the rhinocerase might be a serine protease, although
we have not identified the amino acid present at position 195 (a-
chymotrypsinogen numbering), which should correspond to the
catalytic serine of serine proteases.
Rhinocerase is glycosylated- Several VVSPs are glycosylated [3,8],
and BGSP, the only serine protease identified from B. gabonica
venom has three predicted potential N-glycosylation sites.
Deglycosylation was performed on rhinocerase using N Glycosi-
dase F and the resulting samples were run in 10% SDS-PAGE
along with native rhinocerase. The gel was transferred to a PVDF
membrane and subjected to immune blotting with a rhinocerase-
specific antibody and glycosylation detection using the glycopro-
tein detection module. The immuno blot shows that the molecular
mass of deglycosylated protein is approximately 31 kDa (figure 4A).
Thus, around 5 kDa (14%) of the apparent 36 kDa molecular
mass of the rhinocerase was due to glycosylation. Figure 4B
confirms that the rhinocerase is glycosylated (lane1) and that all
the glycosylation has been removed by the N Glycosidase F (lane2)
consistent with complete transition from 36 kDa to 31 kDa as
shown in figure 4A. The deglycosylated rhinocerase was tested
against Arg-AMC to determine whether it had retained its serine
protease activity after deglycosylation, and it was shown to have
slightly increased activity compared to the native enzyme.
Functional characterization- While some VVSPs have been reported
to have more than one function, eg, crotalase has fibrinogenolytic
and kininogenolytic functions [22], most of the VVSPs have not
been extensively investigated. We therefore sought to characterise
rhinocerase for a range of potential functions such as plasma
clotting, fibrinogenolytic, fibrinolytic, kininogenolytic, plasmino-
gen activator and platelet aggregating activities.
Plasma was clotted rapidly by all concentrations of thrombin
within a few seconds of re-calcification. The venom of B. g.
rhinoceros made a plasma clot in nine minutes. However, no visible
clots were formed with rhinocerase or in the negative control even
after incubating overnight. Therefore the weak plasma clotting
activity of B. g. rhinoceros venom may not be a consequence of
rhinocerase activity.
Rhinocerase was found to degrade the a and b chains of
fibrinogen (figure 5A). The degradation of the a chain was
detectable after 30 minutes of incubation with rhinocerase and this
chain was degraded completely at 90 minutes. The degradation of
the b chain of fibrinogen was detectable after 60 minutes of
Figure 1. Rotofor based separation of B. g. rhinoceros venom proteins. A. SDS-PAGE (10%) was run with 50 mgo fB. g. rhinoceros venom and
stained with Coomassie brilliant blue. Several proteins with different molecular weights are present in this venom. B. 2 mg of venom were mixed with
non-reducing rotofor buffer containing ampholytes with pI 6–8 and separated under non-denaturing conditions. In total 10 fractions (indicated by
the numbers at the top of the gel) were collected. 10 ml of each fraction were run in SDS-PAGE (10%) and stained with Coomassie brilliant blue. C.
20 ml of each rotofor fraction were used to measure serine protease activity using Arg-AMC fluorescent substrate. The data represents the mean 6
S.D. (n=3). The hydrolytic activity measured for fraction 5 was taken as 100%.
doi:10.1371/journal.pone.0009687.g001
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at 180 minutes. Protein fragments (labelled A and B) appeared as
degradation products. The c chain of fibrinogen was not degraded
by rhinocerase even after 180 minutes. Similarly, rhinocerase was
found to degrade the a chain of fibrinogen in human plasma both
in the presence and absence of different concentrations (20 mM to
100 mM) of EDTA (figure 5B). The presence of other plasma
proteins prevented the degradation of the b chain of fibrinogen
from being detected. This clearly suggests that the effect of
rhinocerase on fibrinogen is independent of any divalent cations.
Interestingly, rhinocerase did not cause the formation of a fibrin
clot even after 3 hours. Thus rhinocerase in the venom might be
capable of reducing the amount of functional fibrinogen by
degrading the a and b chains.
Rhinocerase completely dissolved plasma clots generated by
thrombin after incubating overnight. Control clots remained
undissolved. This suggests that rhinocerase might have fibrinolytic
activity. It was found to be capable of cleaving a plasmin substrate,
further supporting the participation of rhinocerase in fibrinolysis
(table 2). No activity was seen in control samples.
Rhinocerase hydrolysed the glandular kallikrein substrate,
suggesting that it might have a kininogenolytic function (table 2).
However, it had no effect on the uPA substrate, though
interestingly the B. g. rhinoceros venom did hydrolyse this substrate
Figure 2. Purification of rhinocerase from rotofor separated venom fractions. A. Superdex 75 gel filtration chromatogram obtained during
the elution of proteins from rotofor separated venom fractions 3 and 4. The peaks were numbered at the particular fractions which were used for
analysis by SDS-PAGE and for analysis of the serine protease activity. B. 100 ml of the selected fractions shown in figure A were used to measure serine
protease activity using Arg-AMC fluorescent substrate. Each bar shows the mean 6 S.D. (n=3). The hydrolytic activity measured for P2 was taken as
100%. C. 100 ml of the selected fractions indicated in figure A were analysed by SDS-PAGE (10%) and silver stained.
doi:10.1371/journal.pone.0009687.g002
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proteases with plasminogen activator activity in this venom.
Rhinocerase was found to be incapable of stimulating platelet
aggregation both in the washed platelets and PRP. This assay was
repeated three times using blood platelets or PRP from three
different donors but no aggregation was observed, although
positive controls (thrombin and collagen related peptide) did
aggregate platelets (figure 6).
Together these data indicate that rhinocerase has effects on a
variety of substrates and suggests that it could have a and b
fibrinogenolytic, fibrinolytic and kininogenolytic activities. Kinetic
analysis shows that Ala-Leu-Lys-AMC is a better substrate than
Ala-Leu-Arg-AMC as the Km value was lower for the former
(table 2). Further to this, the venom of B. g. rhinoceros displayed
plasma clotting and low levels of plasminogen activator activities.
This suggests the presence of additional enzymes, possibly serine
proteases with different functions in this venom.
Effect of inhibitors on rhinocerase activity- VVSPs have been reported
to be sensitive to some but not all serine protease inhibitors. In
order to find out the sensitivity of rhinocerase to serine protease
inhibitors, we tested the effects of two inhibitors.
1.2 mM PMSF is sufficient to inhibit the activity of 10 units of
thrombin. 100 mg of rhinocerase activity were inhibited by
2.3 mM PMSF (figure 7). Comparison of thrombin and
rhinocerase activity shows that the activity of 100 mgo f
rhinocerase is equivalent to only 4.05 units of thrombin, and thus
we conclude that rhinocerase is less sensitive to PMSF than
thrombin. Similarly, the deglycosylated rhinocerase was inhibited
by the same concentration of PMSF as native rhinocerase
indicating that the glycosylated moieties do not affect the binding
of PMSF. A benzamidine affinity column was used to assess the
sensitivity of rhinocerase to benzamidine. Rhinocerase was unable
to bind the column indicating that benzamidine is not an inhibitor
for rhinocerase (data not shown).
Discussion
A novel and highly abundant serine protease, rhinocerase, has
been purified in electrophoretically homogeneous form from the
venom of B. g. rhinoceros. Rhinocerase is clearly distinct from the
serine proteases previously identified in this venom. The apparent
molecular mass of rhinocerase was found to be approximately
Figure 3. Sequence alignment of rhinocerase with other VVSPs. The rhinocerase sequence obtained by Edman degradation was aligned with
BGSP, the only known serine protease sequence from Bitis gabonica (NCBI accession number: AAR24534) and two other VVSP sequences; bothrombin
(NCBI accession number: P81661) and ancrod (NCBI accession number: AAA49195). The sequence identified by Q-TOF is underlined. w indicates
conserved residues, : indicates biochemically more related residues and. indicates biochemically less related residues.
doi:10.1371/journal.pone.0009687.g003
Figure 4. Glycosylation detection on rhinocerase. Deglycosyla-
tion was performed by mixing 100 mg of rhinocerase with 5 units of N
glycosidase F in 50 ml of 0.02M Tris-HCl pH 7.4. 20 mg of glycosylated
(lane1) and deglycosylated (lane2) rhinocerase were run in two separate
SDS-PAGE (10%) gels and transferred to two PVDF membranes. A. One
PVDF membrane was treated with rhinocerase-specific antibody. B. The
second PVDF membrane was used to detect glycosylation using the
ECL glycosylation detection module. Data are representative of three
separate experiments.
doi:10.1371/journal.pone.0009687.g004
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B. gabonica serine proteases. The deglycosylated rhinocerase had a
molecular mass of approximately 31 kDa according to its mobility
in 10% reducing SDS-PAGE. Three other venom serine protease-
containing fractions, all distinct from rhinocerase, have been
isolated from B. gabonica with approximate molecular masses of
32 kDa based on gel chromatography [10]. Pirkle et al. [12]
isolated another serine protease, gabonase, with an estimated
molecular mass of 32 kDa based on SDS-PAGE. As these reports
did not mention the subspecies of the snake, it is unclear whether
they have used Bitis gabonica gabonica or B. g. rhinoceros as we have
used.
The estimated pI of rhinocerase was approximately 6 and again
this did not match with the one completely sequenced B. gabonica
serine protease which has a pI of 8.5 [9]. The N-terminal sequence
of rhinocerase was obtained by Edman degradation and this
matches with the partial N-terminal sequences of the BG-8
fragment [9] and peptide 21 [11] reported previously. Although
not mentioned in their paper, these comparisons suggest that
Francischetti et al. [9] also used B. g. rhinoceros rather than B. g.
gabonica.
The molecular masses of venom serine proteases seem to vary
mainly as a result of their carbohydrate content, since they all
contain a similar number of amino acids i.e. 230-236 [23]. For
example, the three serine protease-containing fractions isolated
from the venom of B. gabonica were reported to have glycosylation
corresponding to 20–25% of their native molecular mass [10].
Similarly, a pro-coagulant enzyme from Agkistrodon rhodostoma [24]
Figure 5. Fibrinogenolytic activity of rhinocerase. Coomassie brilliant blue stained SDS-PAGE gels containing samples taken at different time
intervals during the incubation of 100 mg of rhinocerase with 400 ml (5 mg/ml) of plasminogen-free fibrinogen in 0.05M Tris-HCl; 0.1M NaCl, pH 7.8 or
400 ml of human plasma in the presence and absence of 20 mM EDTA. The numbers at the top of each lane represent the time (in minutes) when
samples were taken during the digestion. A. The degradation profile of plasminogen-free fibrinogen by rhinocerase. a, b and c represent the three
chains of fibrinogen and A and B represent the degradation products. The position of rhinocerase has been labelled on the image. B. The degradation
profile of fibrinogen present in human plasma after removal of albumin and IgG by Proteoprep immunoaffinity albumin and IgG depletion columns.
The position of the a chain of fibrinogen is marked with an arrow. Data are representative of three separate experiments.
doi:10.1371/journal.pone.0009687.g005
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reported to have glycosylation corresponding to 18–24% of their
native molecular mass. In this study, we have found that
rhinocerase has glycosylation corresponding to a slightly lower
percentage (14%) of its native molecular mass.
VVSPs possess three main functions that are responsible for their
systemic effects in envenomed victims: fibrinogenolysis reduces the
functional fibrinogen content; fibrinolysis dissolves the blood clots
and kininogenolysis generates kinin and bradykinin which alter
blood pressure. The preliminary functional analysis of rhinocerase
shows its activity against a variety of substrates and suggests that it
might have all three of the above functions. The fibrinogenolytic
activity of rhinocerase on human plasma in the presence and
absence of a chelating agent suggests that rhinocerase activity is
independent of divalent cations present in plasma. The inability of
rhinocerasetostimulateplateletsindicatesthat itisunlikelytocleave
platelet glycoprotein V or the G protein coupled protease-activated
receptors 1 and 4 which are receptors for thrombin on these cells.
Other VVSPs with platelet aggregating activities have previously
been reported in viper venoms [1,2]. Detailed functional analysis
with biological substrates such as high and low molecular weight
kininogen and specific fibrinopeptides would further confirm the
functions of rhinocerase. However, to our knowledge, rhinocerase is
the first VVSP with the potential to have all three major functions.
Clotting activity was previously reported for the purified gabonase
inB.gabonicavenom[12].Three serineproteasecontainingfractions
(E I to E III) isolated from B. gabonica venom have showed kinin
releasing activity (E I), very low kinin releasing and high fibrinolytic
activities (E II) and lowclotting activity (E III) [10]. Marsh et al. [26]
reported two thrombin-like enzymes from B. gabonica venom, one
Table 2. Specificity of rhinocerase towards various fluorescent substrates.
Activity (Substrate) Enzyme Km
a (mM) Vmax
a(s
21) Kcat
a (s
21)
Kcat/Km x1 0
3a
(mM
21s
21)
Fibrinolytic activity (Ala-Leu-Lys – AMC) Venom 12.2660.56 0.3260.05 - -
Rhinocerase 20.2960.6 - 60.8460.23 3001.29699.57
Kininogenolytic activity (Ala-Leu-Arg – AMC) Venom 14.360.33 0.3860.02 - -
Rhinocerase 32.1960.12 - 104.2864.77 3239.86146.28
Plasminogenolytic activity (Gly-Gly-Arg – AMC) Venom 39.8961.15 0.3760.02 - -
Rhinocerase No activity was detected
aThe values are mean 6 S.D. (n=3).
100 mg of rhinocerase were incubated with different concentrations of various fluorescent substrates at 37uC for 7 minutes. The amount of AMC released was measured
at an excitation wavelength of 366 nm and an emission wavelength of 460 nm at time intervals up to 7 minutes. 100 mgo fB. g. rhinoceros venom were also used at the
same experimental conditions for comparison. Kinetic parameters were determined from Lineweaver-Burk plots.
doi:10.1371/journal.pone.0009687.t002
Figure 6. Effect of rhinocerase on platelets. 100 mg of rhinocerase in a 50 ml volume was added to 450 ml of washed human platelets or platelet
rich plasma in a siliconised glass cuvette in an optical platelet aggregometer with continuous stirring (1200 g) at 37uC. As positive controls, 5 mg/ml
concentration of CRP and 1 U/ml concentration of thrombin were used at same conditions. The traces show nil effect of rhinocerase and aggregation
effects of CRP and thrombin on human washed platelets (A) and platelet rich plasma (B).
doi:10.1371/journal.pone.0009687.g006
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defibrinating activity. Some VVSPs from other snakes have been
found to have two functions, for example crotalase has both
kininogenase and fibrinogenolytic activities [22], and jararacussin
[27], habu [28] and kangshuanmeni [29] are examples of serine
proteases which have both a and b fibrinogenolytic activities. In
common with other VVSPs [2] rhinocerase is less sensitive to PMSF
than thrombin and insensitive to benzamidine. The activity of
deglycosylated rhinocerase on the synthetic fluorescent substrate
and its inhibition by PMSF indicates that glycosylation does not
affect the interaction between rhinocerase and small synthetic
substrates or inhibitors. The glycosylation of rhinocerase might,
however, limit its functions when it is binding to large biological
substrates and inhibitors.
The suggested functions of rhinocerase are consistent with the
effects of systemic envenoming caused by B. g. rhinoceros such as
hypotension (e.g. kininogenolytic activity), clotting disorders (e.g.
fibrinogenolytic activity) and bleeding disorders (e.g. fibrinolytic
activity). It is important to understand that the effects of VVSPs
occur in the context of the functional activities of other potent
biological venom components including other serine proteases,
metalloproteases and phospholipases. Marsh et al. [26] reported
that the venom of B. gabonica causes rapid defibrination together
with widespread haemorrhage, cardiac and pulmonary damage.
Rhinocerase does not catalyse plasma clot formation but
hydrolyses fibrinogen.
In this study, we have purified rhinocerase and characterised its
proteolytic functions. Further functional analysis for factor V,
VIII, XIII activator assays, protein C activator assay and capillary
permeability assay need to be performed to completely character-
ise potential minor functions of this enzyme. The complete
sequence of this protein also needs to be determined to understand
how the multi-functionality relates to the amino acid sequence.
Since the specificity and multi-functional nature of rhinocerase can
only be understood once its structure is determined, this is a focus
of ongoing work. The complete understanding of the sequence,
structure and functional relationships of rhinocerase could lead to
clinical studies to investigate the potential of this enzyme being
used to treat human haemostatic disorders such as heart attack,
strokes and hypotension.
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